

**WE CLAIM:**

1. An isolated peptide, consisting of an amino acid sequence selected from the group consisting of amino acids 80-109, 87-98, 108-119, 121-132 or 143-154 of SEQ ID NO: 1.
2. A composition useful in stimulating a CD4<sup>+</sup> T cell response, comprising the isolated peptide of claim 1, and an adjuvant.
3. A composition useful in stimulating a T cell response in an subject, comprising the isolated peptide of claim 1, and at least one additional peptide.
4. The composition of claim 3, wherein said at least one additional peptide consists of an amino acid sequence derived from NY-ESO-1.
5. The composition of claim 3, wherein said at least one additional peptide binds to an MHC Class I molecule and stimulates a CD8<sup>+</sup> T cell response.
6. The composition of claim 3, wherein said at least one additional peptide binds to an MHC Class II molecule and stimulates a CD4<sup>+</sup> T cell response.
7. The composition of claim 3, further comprising a pharmaceutically acceptable carrier.
8. The composition of claim 7, wherein said pharmaceutically acceptable carrier is an adjuvant.
9. An isolated nucleic acid molecule consisting of a nucleotide sequence which encodes a peptide, the amino acid sequence of which is selected from the group consisting of amino acids 80-109, 87-98, 108-119, 121-132 or 143-154 of SEQ ID NO: 1.
10. Expression vector comprising the isolated nucleic acid molecule of claim 9, operably linked to a promoter.
11. Recombinant cell comprising the isolated nucleic acid molecule of claim 9.
12. Recombinant cell comprising the expression vector of claim 10.

13. An isolated CD4<sup>+</sup> T cell which recognizes a complex of the isolated peptide of claim 1 and an MHC Class II molecule.